Curewize Health

Company Overview

Snapshot

Founded in February 2013 by Jennifer Yarden, Curewize Health operated with 1–10 employees. The company raised $1M across two funding rounds. In April 2018, Curewize Health successfully completed a clinical trial on a lab test designed to identify optimal treatment regimens for acute lymphoblastic leukemia patients.

Business overview

Curewize Health was a clinical research and commercialization company focused on advancing personalized treatments for cancers prevalent in children, adolescents, and young adults. Its core product family, ProALL, consisted of microRNA-based predictive tests for early diagnosis and monitoring of acute lymphoblastic leukemia patients. The company also conducted R&D for precision lab tests to guide specific therapies and developed the ProState blood test for high-accuracy prostate cancer detection, aiming to prevent overtreatment. Curewize Health operated within the Health Tech & Life Sciences sector, specifically in Medical Devices, Medical Treatment & Therapeutics, and Diagnostics Devices, serving patients and healthcare providers.

Strategic signal

In April 2018, Curewize Health announced the successful completion of a clinical trial for its lab test, which identifies optimal treatment regimens for acute lymphoblastic leukemia patients. This milestone validated the company's microRNA-based diagnostic approach and signaled its readiness to prepare for a European launch in 2019, demonstrating significant progress in bringing personalized cancer diagnostics to market.

Company Intelligence Q&A

What was Curewize Health's primary focus?

Curewize Health focused on advancing personalized treatments for cancers common in children, adolescents, and young adults, utilizing microRNA-based predictive tests and companion diagnostics.

What was the company's lead product?

The company's lead product family was ProALL, which consisted of microRNA-based predictive tests for the early diagnosis and monitoring of acute lymphoblastic leukemia patients.

When did Curewize Health complete a significant clinical trial?

In April 2018, Curewize Health successfully completed a clinical trial on a lab test designed to reveal optimal treatment regimens for acute lymphoblastic leukemia patients.

What was the total capital raised by Curewize Health?

Curewize Health raised a total of $1M across two funding rounds.

Which investor participated in Curewize Health's funding rounds?

Youdim Pharmaceuticals participated in a funding round for Curewize Health in September 2016.